The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer

The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer

The definitive characterization of common cancer stem cell (CSCs) subpopulations in breast cancer subtypes with distinct genotypic and phenotypic features remains an ongoing challenge. In this study, we have used a non-biased genome wide screening approach to identify transcriptional networks that m...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Walsh, CA, Akrap, N, Garre, E, Magnusson, Y, Harrison, H, Andersson, D, Jonasson, E, Rafnsdottir, S, Choudhry, H, Buffa, F, Ragoussis, J, Ståhlberg, A, Harris, A, Landberg, G
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	Public Library of Science 2020

Míreanna comhchosúla

The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer.
de réir: Claire A Walsh, et al.
Foilsithe / Cruthaithe: (2020-01-01)

Induction of resistance to neurotrophic tropomyosin‐receptor kinase inhibitors by HMGCS2 via a mevalonate pathway
de réir: Yasuhiro Kato, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Identification of Distinct Breast Cancer Stem Cell Populations Based on Single-Cell Analyses of Functionally Enriched Stem and Progenitor Pools
de réir: Nina Akrap, et al.
Foilsithe / Cruthaithe: (2016-01-01)

Proteomics of cell‐free breast cancer scaffolds identify clinically relevant imprinted proteins and cancer‐progressing properties
de réir: Anna Gustafsson, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion
de réir: Sara Rhost, et al.
Foilsithe / Cruthaithe: (2018-11-01)

Expression of HMGCS2 and its correlation with clinopathological characteristics in bladder cancer
de réir: ZHU Shuai, et al.
Foilsithe / Cruthaithe: (2021-12-01)

Inhibition of Lung Squamous Cancer Target HMGCS1 Promotes Cellular Ferroptosis
de réir: Yinyun NI, et al.
Foilsithe / Cruthaithe: (2024-05-01)

Hmgcs2 is the hub gene in diabetic cardiomyopathy and is negatively regulated by Hmgcs2, promoting high glucose‐induced cardiomyocyte injury
de réir: Ying Wang, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Differentially expressed miRNAs in Luminal and Basal-like breast cancer
de réir: Ming-Juan ZHAO, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Mevalonate Metabolism in Cancer Stemness and Trained Immunity
de réir: Georg Gruenbacher, et al.
Foilsithe / Cruthaithe: (2018-09-01)

Mevalonate metabolism governs cancer immune surveillance
de réir: Georg Gruenbacher, et al.
Foilsithe / Cruthaithe: (2017-10-01)

The Effect of Hypoxic and Normoxic Culturing Conditions in Different Breast Cancer 3D Model Systems
de réir: Andreas Svanström, et al.
Foilsithe / Cruthaithe: (2021-11-01)

Debottlenecking mevalonate pathway for antimalarial drug precursor amorphadiene biosynthesis in Yarrowia lipolytica
de réir: Monireh Marsafari, et al.
Foilsithe / Cruthaithe: (2020-06-01)

HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells
de réir: Fat-Moon Suk, et al.
Foilsithe / Cruthaithe: (2022-11-01)

The Mevalonate Pathway, a Metabolic Target in Cancer Therapy
de réir: Borja Guerra, et al.
Foilsithe / Cruthaithe: (2021-02-01)

Pathology-based deep learning features for predicting basal and luminal subtypes in bladder cancer
de réir: Zongtai Zheng, et al.
Foilsithe / Cruthaithe: (2025-02-01)

Patient-derived scaffolds representing breast cancer microenvironments influence chemotherapy responses in adapted cancer cells consistent with clinical features
de réir: Maria Carmen Leiva, et al.
Foilsithe / Cruthaithe: (2023-12-01)

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer
de réir: Karoline Berger, et al.
Foilsithe / Cruthaithe: (2021-02-01)

Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
de réir: Andy Göbel, et al.
Foilsithe / Cruthaithe: (2020-07-01)

Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy
de réir: Linyuan Xue, et al.
Foilsithe / Cruthaithe: (2020-08-01)

Potential Role of HMGCS2 in Tumor Angiogenesis in Colorectal Cancer and Its Potential Use as a Diagnostic Marker
de réir: Kejian Zou, et al.
Foilsithe / Cruthaithe: (2019-01-01)

Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome
de réir: Hoffmann Georg F, et al.
Foilsithe / Cruthaithe: (2006-04-01)

Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis
de réir: Maria B. Padua, et al.
Foilsithe / Cruthaithe: (2018-05-01)

Targeting HMGCS1 restores chemotherapy sensitivity in acute myeloid leukemia
de réir: Cheng Zhou, et al.
Foilsithe / Cruthaithe: (2024-07-01)

A Luminous Precursor in the Extremely Bright GRB 230307A
de réir: S. Dichiara, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study
de réir: Humberto Parada, et al.
Foilsithe / Cruthaithe: (2017-12-01)

Cellular organization and molecular differentiation model of breast cancer-associated fibroblasts
de réir: Susann Busch, et al.
Foilsithe / Cruthaithe: (2017-04-01)

Immunohistochemical Evaluation of Basal and Luminal Markers in Bladder Cancer: A Study from a Single Institution
de réir: Anh Toan Do, et al.
Foilsithe / Cruthaithe: (2024-12-01)

Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use
de réir: Vipulkumar Dadhania, et al.
Foilsithe / Cruthaithe: (2016-10-01)

Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers.
de réir: Doris Kim, et al.
Foilsithe / Cruthaithe: (2016-01-01)

Transcriptome analysis of basal and luminal tumor-initiating cells in ErbB2-driven breast cancer
de réir: Nicholas Borcherding, et al.
Foilsithe / Cruthaithe: (2015-06-01)

HMGCS2 and AMACR as potential targets linking mitochondrial dysfunction and ulcerative colitis
de réir: Rui Zhu, et al.
Foilsithe / Cruthaithe: (2024-12-01)

Liver HMGCS2 is critical in the maintenance of liver lipid homeostasis during fasting
de réir: Yunfeng Zhou, et al.
Foilsithe / Cruthaithe: (2023-05-01)

Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis
de réir: Shaza Asif, et al.
Foilsithe / Cruthaithe: (2022-07-01)

KLF13 suppresses the proliferation and growth of colorectal cancer cells through transcriptionally inhibiting HMGCS1-mediated cholesterol biosynthesis
de réir: Weilong Yao, et al.
Foilsithe / Cruthaithe: (2020-06-01)

The mevalonate pathway in <it>C. Elegans</it>
de réir: Rauthan Manish, et al.
Foilsithe / Cruthaithe: (2011-12-01)

Mevalonate Metabolism in Immuno-Oncology
de réir: Georg Gruenbacher, et al.
Foilsithe / Cruthaithe: (2017-12-01)

Expression of housekeeping genes varies depending on mevalonate pathway inhibition in cancer cells
de réir: Nanami Irie, et al.
Foilsithe / Cruthaithe: (2023-07-01)

NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer
de réir: Zefu Liu, et al.
Foilsithe / Cruthaithe: (2023-08-01)

Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer
de réir: Natalia Ricco, et al.
Foilsithe / Cruthaithe: (2019-09-01)